PREMATURE OVARIAN INSUFFICIENCY

Öz

Premature Ovarian Insufficiency POF describes the diminished ovarian functions before the age 40. Related with the clinics of POF, menopausal symptoms, sub fertility, long term cardiovascular dysfunctions, osteoporosis and psychological problems are mentioned. Among the etiological factors most of them are idiopathic, and the less frequently pronounced items consists of oopherectomy, chemotherapy or radiotherapy, genetic factors, autoimmune adrenal and throid problems and FSH reseptor defects. Related with the infertility treatments no intervention has been found to improve conception rates. IVF with donor oocytes is the only treatment option.

Anahtar Kelimeler

• Premature ovarian insufficiency,Infertility

PREMATUR OVER YETERSiZLiGi

Öz

Prematiir over yetersizligi POY , 40 yaşımdan once, overlerin fonksiyon kapasitesindeki azalmay1 ifade eder. POY ile menapozal semptomlar başlar, subfertilite, uzun donemde ortaya çıkabilecek kardiovaskiiler problemler, osteoporoz riski ve hatta psikolojik sıkıntilar oluşabilecek komplikasyonlar arasmdad1r. Etiyolojik faktörler içinde çogu idiopatik olmakla birlikte, ooferektomi, kemoterapi, radyoterapi, genetik bozukluklar, otoimmiine adrenal ve tiroid hastahklan ve FSH reseptör defektleri sayilabilir. Tedavinin temelinde estrojen ve progesteron içeren kombine preparatlarla hormon replasmam vardır. Spontan gebelik çok az gorülür, infertilite tedavilerinin başarısı yok denecek kadar azdır, çocuk sahibi olma ancak ülkemizde yasal olmayan donor oositli IVF ile mümkündür.

Anahtar Kelimeler

• Prematlir over yetersizligi,nfertilite

Kaynakça

1. 1. Nelson LM. Clinical Practice: Primary ovarian insufficiency. N Eng J Med 2009; 360:606–14.
2. 2. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986; 67:604–6.
3. 3. Liao KL, Wood N, Conway GS. Premature menopause and psychological well-being. J Psycho Obstet Gynaecol 2000; 21:167–74.
4. 4. Munster K, Helm P, Schmidt L. Secondary amenorrhoea: prevalence and medical contact – a cross-sectional study from a Danish county. Br J Obstet Gynaecol 2002; 99:430–3.
5. 5. Bakalov VK, Anasti JN, Calis KA, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertil Steril 2005; 84:958–65.
6. 6. Aittomäki K, Lucena JLD, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995; 82:959–68.
7. 7. Rajangam S, Nanjappa L. Cytogenetic studies in amenorrhea. Saudi Med J 2007; 28:187-92.
8. 8. Simpson JL. Genetic and phenotypic heterogeneity in ovarian failure: overview of selected candidate genes. Ann N Y Acad Sci 2008; 1135:146-54.

9. 9. Massad-Costa AM, da Silva ID, Affonso R, Soares JM, Jr., Nunes MG, de Lima GR, Baracat EC. Gene analysis in patients with premature ovarian failure or gonadal dysgenesis: a preliminary study. Maturitas 2007; 57:399-404.
10. 10. Goswami R, Goswami D, Kabra M, Gupta N, Dubey S, Dadhwal V. Prevalence of the triple X syndrome in phenotypically normal women with premature ovarian failure and its association with autoimmune thyroid disorders. Fertil Steril 2003; 80:1052–4.
11. 11. Murray A, Webb J, Grimley S, et al. Studies of FRAXA and FRAXE in women with premeture ovarian failure. J Med Genet 1998;35:637-40.
12. 12. Sherman SL., Premeture ovarian failure in the fragile X syndrome, Am J Med Genet 2000;97:189-94.
13. 13. ACOG committe opinion. No. 338: Screening for fragile X syndrome, Obstet Gyncol 2006;107:1483.
14. 14. Conway GS,Kaltsas G, Patel A, et al. Characterization of idiopathic premature ovaian failure. Fertil Steril 1996;65:337-41.
15. 15. Luborsky J, Llanes B, Davies S, et al. Ovarian autoimmunity :greater frequency of autoantibodies in premature menopause and unexplained infertility than in the general population. Clin Immunol 1999;90:368-74.
16. 16. Bakalov VK, Vanderhoof VH, Bondy CA, et al. Adrenal antibodies detect asymotomatic auto-immune adrenal insufficiency in young womwn with spontaneous premature ovarian failure . Hum Reprod 2002; 17:2096-100.
17. 17. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and womwn from the UK. Osteopor Inter 2008; 19:385-97.
18. 18. Shulter LT, Rhodes DJ. Gostout BS, Grossart BR, Rocca WA. Premature menopause or early menopause :long-term health consequences. Maturitas 2010; 65:161-6.
19. 19. Sturdee DW, Pines A. International Menopause Socienty Writing Group, Updated IMS recommendatioms on postmenopausal hormone therapy and preventive atrategies for midlife health. Climacter 2011; 14:302-20.
20. 20. Position Statement Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17:242-55.
21. 21. Vujovic S, Brincat M, Erel T, Gambacciani M, Lambrinoudaki I, Moen MH. et al. EMAS position statement: Managing women with premature ovarian failure. Maturitas 2010; 67:91-3.
22. 22. van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999; 5:483-92.
23. 23. Bidet M, Bachelot A,Touraine P. Premature ovarian failure: predictability of intermittend ovarian function and response to ovulation induction agents. Cur Opin Obstet Gynecol 2008; 20416-20.